WSI Co Ltd
WSI Co Ltd has a market price of 2160.0 KRW and a market cap of 73680487920.0 KRW, with a price-to-book ratio of 1.24 and a price-to-tangible-book ratio of 1.24. The company's enterprise value to EBITDA is 20.76, and its enterprise value to revenue is 1.53. The company's liquidity position is characterized by a current ratio of 3.42 and a debt-to-equity ratio of 0.21, indicating a relatively strong liquidity position. The company's profitability metrics are concerning, with a return on equity of -0.0609 and a return on assets of -0.0418, both significantly below the industry median. The company reported a net loss of -3630174980.0 KRW, despite a gross profit of 15410724000.0 KRW and an operating income of 3805405660.0 KRW. The negative net income suggests operational inefficiencies or significant non-operating expenses. WSI Co Ltd's revenue is primarily derived from the sale of pharmaceuticals and medical devices, with a focus on wholesale and retail operations. The company's geographic exposure is concentrated in South Korea, and there is no indication of significant international revenue diversification. The company's revenue concentration in a single geographic region may expose it to local economic and regulatory risks. The company's growth trajectory is mixed, with a revenue of 51706061280.0 KRW in the latest period. However, the company's free cash flow is negative at -2696819840.0 KRW, and capital expenditures are -1030504380.0 KRW, indicating a need for significant investment to sustain operations. The company's operating cash flow of 3090125810.0 KRW provides some liquidity, but the negative free cash flow suggests that the company is not generating sufficient cash to fund its operations and investments. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. However, the key flag of negative net cash after subtracting total debt highlights a potential liquidity constraint. The company's debt-to-equity ratio of 0.21 is relatively low, but the negative net cash position suggests that the company may need to raise additional capital or manage its debt more effectively. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent financial performance and risk profile suggest that it is in a period of transition, with a need to address its profitability and liquidity challenges.
Business. WSI Co Ltd is a Korea-based company engaged in the wholesale and retail of pharmaceuticals and medical devices, as well as the manufacturing and development of medical robots and medical devices, and the manufacturing, sales, and R&D of pharmaceuticals.
Classification. WSI Co Ltd is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.
- WSI Co Ltd is a South Korea-based company with a focus on pharmaceuticals and medical devices, but it is currently reporting a net loss.
- The company's liquidity position is relatively strong, with a current ratio of 3.42 and a debt-to-equity ratio of 0.21.
- WSI Co Ltd's profitability metrics are below industry medians, with a return on equity of -0.0609 and a return on assets of -0.0418.
- The company's revenue is concentrated in South Korea, and it has a negative free cash flow, indicating a need for significant investment.
- The company's risk assessment indicates a medium liquidity risk and a low dilution risk, but it has a key flag of negative net cash after subtracting total debt.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.